SMARCB1 and neoplasm: Potential mutations of PASG/LSH have been identified in leukaemia (Lee et al, 2000); BRG1 genetic alterations occur in several tumour types and the reintroduction of the gene inhibits cell growth (Medina et al, 2005); helicase-like transcription factor (HLTF) undergoes methylation-associated silencing in different neoplasms (Esteller, 2005a); and SNF5 shows inactivating somatic and germline mutations in malignant rhabdoid tumours (Imbalzano and Jones, 2005).